In the Celebrex case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Pfizer’s blockbuster anti-inflammatory drug, Celebrex. The case alleges that Pfizer procured a patent by committing Walker Process fraud and then filed patent litigation against generic drugmakers Teva Watson and Mylan, to delay their entry into the market with less-expensive generic versions of Celebrex , forcing direct purchasers to pay higher branded prices rather than lower generic prices for longer than they otherwise would have. Celebrex had annual sales of over $1 billion during the relevant time, making the overcharge paid by direct purchasers quite substantial.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Filed on 09/13/2014
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Joseph T. Lukens email@example.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn firstname.lastname@example.org Phone (215) 277-5770 Fax (215) 277-5771